74007-20-8
Chemical Structure
trans-Doxercalciferol
- CAS No.: 74007-20-8
- Formula:C28H44O2
- Molecular Weight:412.65
IUPAC Name: (1R,3S,E)-5-(2-((1R,3aS,7aR,E)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol
InChIKey: HKXBNHCUPKIYDM-HBZIUUSASA-N
SMILES: C=C([C@H](C[C@H](O)C/1)O)C1=C\C=C2[C@@]3([H])[C@@](CCC\2)(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC3
Biological Activity: trans-Doxercalciferol is an isomer of Doxercalciferol (HY-32348). Doxercalciferol is a vitamin D receptor agonist. Doxercalciferol reduces proteinuria, podocyte injury, mesangial expansion, extracellular matrix accumulation, macrophage infiltration, oxidative stress, proinflammatory cytokines, profibrotic growth factors, renal neutral lipid accumulation, albuminuria and glomerulosclerosis. Doxercalciferol alleviates high-salt diet-induced myocardial hypertrophy. trans-Doxercalciferol is used for the research of diet-induced obesity-related nephropathy, diabetic nephropathy, myocardial hypertrophy, cardiac dysfunction and secondary hyperparathyroidism[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
trans-Doxercalciferol | 98.20% | trans-Doxercalciferol is an isomer of Doxercalciferol (HY-32348). Doxercalciferol is a vitamin D receptor agonist. Doxercalciferol reduces proteinuria, podocyte injury, mesangial expansion, extracellular matrix accumulation, macrophage infiltration, oxidative stress, proinflammatory cytokines, profibrotic growth factors, renal neutral lipid accumulation, albuminuria and glomerulosclerosis. Doxercalciferol alleviates high-salt diet-induced myocardial hypertrophy. trans-Doxercalciferol is used for the research of diet-induced obesity-related nephropathy, diabetic nephropathy, myocardial hypertrophy, cardiac dysfunction and secondary hyperparathyroidism. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Wang XX, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol. 2011;300(3):F801-F810. [Content Brief]
- [2]. Zhang Y, et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol. 2009 Sep;297(3):F791-801. [Content Brief]
- [3]. Choi JH, et al. Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats. J Card Fail. 2011;17(12):1051-1058. [Content Brief]
- [4]. Kubodera N, et al. A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol. Molecules. 2009;14(10):3869-3880. Published 2009 Sep 29. [Content Brief]
- [5]. Wesseling-Perry K, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011;79(1):112-119. [Content Brief]
Keywords
